Results 61 to 70 of about 2,554,329 (307)

Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya, Veronica Moroz, Juliet Hale, Vesna Pavasovic, Rachel Hobson, Patricia Sartori, Daniel Saunders, Mark Powis, Gordan M. Vujanic, Stephen Baker, Kathy Pritchard‐Jones   +10 more
wiley   +1 more source

miR-204-5p Represses Bone Metastasis via Inactivating NF-κB Signaling in Prostate Cancer

Molecular Therapy: Nucleic Acids, 2019
The prime issue derived from prostate cancer (PCa) is its high prevalence to metastasize to bone. MicroRNA-204-5p (miR-204-5p) has been reported to be involved in the development and metastasis in a variety of cancers.
Qingde Wa, Sheng Huang, Jincheng Pan, Yubo Tang, Shaofu He, Xiaodong Fu, Xinsheng Peng, Xiao Chen, Chunxiao Yang, Dong Ren, Yan Huang, Zhuangwen Liao, Shuai Huang, Changye Zou   +13 more
doaj   +1 more source

Risk factors and nomogram for newly diagnosis of bone metastasis in bladder cancer

Medicine, 2020
Bladder cancer (BC) is the second most common urogenital malignant tumor. Bone metastasis (BM) is not common in BC patients, and there are only few studies on it.
Zhangheng Huang, Chuan Hu, Yuexin Tong, Chengliang Zhao   +3 more
semanticscholar   +1 more source

Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High‐Risk Neuroblastoma: A Multi‐Institutional Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman, Madeleine King, Rajen Mody, Sara‐Jane Onyeama, Araz Marachelian, Thomas Cash, Sara M. Federico, Meaghan Granger, Ami V. Desai, Suzanne Shusterman, Jennifer H. Foster, Elizabeth Sokol, Chelsee Greer, Keri Streby, Holly J. Meany, Kieuhoa T. Vo, Margaret E. Macy, Rochelle Bagatell   +17 more
wiley   +1 more source

Peran Terapi Akupunktur pada Nyeri Tulang Metastasis

Indonesian Journal of Cancer, 2016
Bone pain caused by cancer is a common complication in bone metastasis. Bone pain has the characteristic triad of pain including continuous pain, spontaneous pain and incident pain.
HASAN MIHARDJA, ZULHAFIZ MUFTI AGUNG
doaj   +1 more source

Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth

Journal of Experimental Medicine, 2020
This study identifies a novel population of CD204+IL4R+ bone metastasis–associated macrophages (BoMAMs) in mouse models and patient samples. These BoMAMs, derived from CCR2-recruited monocytes but not from CD169+ resident macrophages, significantly ...
Ruo-Yu Ma, Hui Zhang, Xue-Feng Li, Cheng-Bin Zhang, C. Selli, G. Tagliavini, Alyson D. Lam, S. Prost, A. Sims, Hai-Yan Hu, T. Ying, Zhan Wang, Zhaoming Ye, J. Pollard, Binzhi Qian   +14 more
semanticscholar   +1 more source

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson, Menna Shamma, Upeka Senanayake, Shaimaa Sahmoud, Kathleen Duffin, Victoria Howard, David King, Ayesha Fathani, Blanche Lumb, Andrei Pobischan, Irum Latif Memon, Monzir Ahmed, Rhian Thomas, Gerard Millen, Yasmeen Alomari, Sucheta Vaidya, Lynley V. Marshall, Sally L. George, Ramya Ramanujachar, Juliet Gray, Paola Angelini   +20 more
wiley   +1 more source

RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies

Frontiers in Cell and Developmental Biology, 2020
Breast cancer remains one of the most life-threatening tumors affecting women. Most patients with advanced breast cancer eventually develop metastatic diseases, which cause significant morbidity and mortality.
Xiaoqiu Wu, Fangfei Li, L. Dang, C. Liang, Aiping Lu, Ge Zhang   +5 more
semanticscholar   +1 more source

Animal models of bone metastasis [PDF]

Cancer, 2003
Animal models will continue to be indispensable to investigate the pathogenesis of bone metastasis in vivo, conduct preclinical chemotherapeutic, chemoprevention and genetic therapy studies, test gene delivery mechanisms, and identify metastasis suppressor and inducer genes.
Thomas J, Rosol, Sarah H, Tannehill-Gregg, Bruce E, LeRoy, Stefanie, Mandl, Christopher H, Contag   +4 more
openaire   +4 more sources

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Thomas Scharschmidt, Kathryn R. Tringale, Oscar Lopez Nunez, Jiaqi Hu, Donald A. Barkauskas, Rajkumar Venkatramani, Sheri L. Spunt, Aaron R. Weiss, Noah C. Federman   +11 more
wiley   +1 more source